Treatment of rheumatoid polyarthritis at Dakar: Efficacy tolerance and cost;Traitement de la polyarthrite rhumatoide par le methotrexate a Dakar: Efficacite, tolerance et cout

Cahiers Sante

Volumn 10, Issue 1, 2000, Pages 65-68

  Ka, Mamadou Mourtalla ^a   Diallo, Saidou ^a   Ka, Elhadji Fary ^a   Diop, Bernard Marcel ^a   Pouye, Abdoulaye ^a   Mbengue, Mouhamadou ^a   Leye, Abdoulaye ^a   Diouf, Boucar ^a   Diop, Thérèse Moreira ^a  

^a Centre Hospitalier Universitaire Aristide Le Dantec de Dakar   (Senegal)

Author keywords

[No Author keywords available]

Indexed keywords

GOLD SALT; METHOTREXATE;

ADULT; ARTICLE; BRONCHITIS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MALE; PATIENT COMPLIANCE; RHEUMATOID ARTHRITIS;

EID: 0034082361     PISSN: 11575999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Kremer JM, Lee JK. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum 1986 ; 29 : 822.
2. Fehlauer CS, Carson CW, Cannon GW, et al. Methotrexate therapy in rheumatoid arthritis : 2 years retrospective follow-up study. J Rheum 1989 ; 16 : 307-12.
3. O'Dell JR, Case L. The treatment of rheumatoid arthritis in 1995 : results of a survey. Arthritis Rheum 1995 ; 38 (suppl.) : S366.
4. Brion N, Paule B. Les utilisations non cancérologiques du methotrexate. La Presse Médicale 1996 ; 25 : 1929-34.
5. Arnette FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988 ; 31 : 315-24.
6. Hoffmeister RT. Methotrexate in rheumatoid arthritis. Arthritis Rheum 1972 ; 15 : 114.
7. Felson DT, Anderson TT, Meean RF The rheumatoid arthritis : a meta analysis of published clinicals trials. Arthritis Rheum 1992 ; 35 1117-25
8. Ahern MJ, Chandran G. Symptom modifying antirheumatic drugs : a comparative review. Clin Immunother 1995 ; 3 : 196-217.
9. Pinals RS, Masi AT, Larsen RA, and the Subcommittee for criteria of remission in rheumatoïd arthritis of the American Rheumatism Association. Diagnostic and therapeutic criteria committee. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981 ; 24 : 1308-15.
10. Kremer JM, Reynes LI, Bartholomew LE. Severe flare of rheumatoid arthritis after discontinuation of long term methotrexate therapy. Double blind study. Am J Med 1987 ; 82 : 781.
11. Kremer JM, Phelps CT. Long-terme prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. Arthritis Rheum 1992 ; 35 : 138-45.
12. Chang DM, Weinblatt ME, Schur PH. The effects of methotrexate on interleukin 1 in patients with rheumatoid arthritis. J Rheumatol 1992 ; 11 : 1678-82.
13. Berthelot JM, Glemarec J, Chiffoleau A, Maugars Y, Prost A. Traitement à faibles doses par le methotrexate dans la polyarthrite rhumatoide. Facteurs de risque des complications graves. Thérapie 1997 ; 52 : 111-6.
14. Hilliquin P, Laoussadi S, Menkes CJ. Traitement de la polyarthrite rhumatoïde par le méthotrexate. Rev Rhumatisme 1991 ; 58 : 419-26.
15. Gutierrez-Urena S, Molina JF, Garica CO, Cuellar ML, Espinoza LR. Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum 1996 ; 39 : 272-6.
16. Ramsey-Goldman R, Schilling E. Immunosuppressive drug use during pregnancy. Rheum Dis Clin North Am 1997 ; 23 : 149-67.
17. Kremer JM, Atarcon GS, Lighfoot RW, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994 ; 37 : 316-28.
18. Ka MM, Herve P, Leguenno B, et al Faible prévalence des anticorps anti-virus de l'hépatite C dans le carcinome hépatocellulaire au Sénégal. Ann Gastroenterol Hepatol 1995 ; 31 . 329-32.